Compare

Compare stocks side by side

Pick up to 3 companies to see where each one is stronger or weaker.

LYCAREGN

Lycia Therapeutics Inc.

LYCA · $26.31

—Not rated

Regeneron Pharmaceuticals, Inc.

REGN · $782.04

73Good

Area by area

Overall Quant Score

How does it look overall? (out of 100)

LYCA

n/a

REGN

73/100

Quality

Is it a profitable, well-run business?

LYCA

n/a

REGN

6.2/10

Growth

Is the company growing?

LYCA

n/a

REGN

4.5/10

Valuation

Is the price reasonable? (higher = cheaper)

LYCA

n/a

REGN

6.9/10

Risk

How risky are the shares? (higher = lower risk)

LYCA

10.0/10

REGN

8.1/10

Momentum

Is the share price trending up?

LYCA

n/a

REGN

8.4/10

Financial strength

Is the balance sheet healthy?

LYCA

n/a

REGN

9.7/10

The balanced view

Model-generated

Lycia Therapeutics Inc.

There isn't enough financial data to give this stock a reliable overall score.

Leads on: risk

Best feature: relatively low risk (Beta (vs. market): 0.00)

Watch out: weakest area: risk profile (Beta (vs. market): 0.00)

Regeneron Pharmaceuticals, Inc.

This company scores above average, with a healthy balance sheet and a positive price trend.

Leads on: quality, growth, valuation, momentum, financial strength

Best feature: healthy balance sheet (Altman Z-Score: 7.29)

Watch out: weakest area: growth potential (Revenue growth (FY): 1.0%)

Different strengths suit different goals — a higher score in one area doesn’t make a stock the better choice for everyone.